



## Ravindra Majeti MD, PhD

Professor of Medicine (Hematology)

Medicine - Hematology

 Curriculum Vitae available Online

### CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr

MC 6560

Stanford, CA 94305

**Tel** (650) 498-6000

**Fax** (650) 725-6910

### ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Peggy Cuadro - Administrative Associate

**Email** mcuadro@stanford.edu

**Tel** (650) 723-5569

### Bio

---

#### BIO

Ravi Majeti MD, PhD is Professor of Medicine, Chief of the Division of Hematology, and Member of the Institute for Stem Cell Biology and Regenerative Medicine at the Stanford University School of Medicine. He was an undergraduate at Harvard, earned his MD and PhD from UCSF, and trained in Internal Medicine at Brigham and Women's Hospital in Boston. Dr. Majeti completed his Hematology Fellowship at Stanford, and is a board-certified hematologist. While at Stanford, he completed post-doctoral training in the laboratory of Irving Weissman, where he investigated acute myeloid leukemia (AML) stem cells and therapeutic targeting with anti-CD47 antibodies. With Dr. Weissman, he developed a humanized anti-CD47 antibody, initiated first-in-human clinical trials. Dr. Majeti directs an active NIH-funded laboratory that focuses on the molecular characterization and therapeutic targeting of leukemia stem cells in human hematologic disorders, particularly AML, and has published >90 peer-reviewed articles. He is a recipient of the Burroughs Wellcome Career Award for Medical Scientists, the New York Stem Cell Foundation Robertson Investigator Award, and the Leukemia and Lymphoma Society Scholar Award. Dr. Majeti is currently a member of the Committee on Scientific Affairs for the American Society of Hematology (ASH) and serves of the editorial board of Blood and eLife.

#### CLINICAL FOCUS

- Hematology

#### ACADEMIC APPOINTMENTS

- Professor, Medicine - Hematology
- Member, Bio-X
- Member, Institute for Stem Cell Biology and Regenerative Medicine
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

#### ADMINISTRATIVE APPOINTMENTS

- Chief, Division of Hematology, (2017- present)
- Assistant Director, Stanford Ludwig Center for Cancer Stem Cell Research, (2014- present)

- Co-Director, Lymphoma and Leukemia Program - Stanford Cancer Institute, (2014- present)
- Co-Director, Translational Research Program - Internal Medicine Residency, (2013-2017)

## HONORS AND AWARDS

- Scholar Award, Leukemia and Lymphoma Society (2015)
- Robertson Investigator Award, New York Stem Cell Foundation (2011)
- Career Award for Medical Scientists, Burroughs Wellcome Fund (2008)

## BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Hematology - Committee on Myeloid Neoplasia (2013 - present)

## PROFESSIONAL EDUCATION

- Medical Education: University of California at San Francisco School of Medicine (2002) CA
- Residency: Brigham and Women's Hospital Harvard Medical School (2004) MA
- Board Certification: Hematology, American Board of Internal Medicine (2007)
- Fellowship: Stanford University Medical Center (2008) CA

## LINKS

- Lab Website: <http://majetilab.stanford.edu/>

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that is rapidly fatal within months if untreated. Even with aggressive treatment, including high dose chemotherapy and bone marrow transplantation, five-year overall survival rates range between 30-40%. A growing body of evidence indicates that not all cells in this cancer are the same, and that there is a rare population of leukemia stem cells (LSC) that are responsible for maintaining the disease. These findings have led to the idea that in order to cure this cancer, the LSC must be eliminated, while at the same time sparing the normal blood forming stem cells within the bone marrow.

The overall goal of our research is to identify molecular and genetic differences between human AML stem cells and their normal counterparts, and then to develop therapeutic strategies directed against these targets. We utilize bioinformatics, genomics, and functional methods to investigate genes and pathways preferentially expressed or activated in LSC. From this analysis, we have identified a number of factors, including several cell surface protein markers that are more highly expressed on AML LSC compared to their normal counterparts. We have focused on one of these markers, CD47, that contributes to leukemia development by blocking the ingestion and removal of leukemia cells by cells of the immune system. Most significantly, we determined that blocking monoclonal antibodies directed against CD47 targeted LSC and depleted leukemia in mouse pre-clinical models. We have now developed a clinical grade humanized anti-CD47 antibody that is in clinical trials at the Stanford Cancer Center.

Our research has also investigated the development of AML from normal blood forming, or hematopoietic, stem cells (HSC). Genomic studies have determined that most cases of AML are associated with an average of 5 mutations, raising the question of how these multiple mutations accumulate in a single lineage of cells. We hypothesized that since HSC are the only long-lived, self-propagating cells in the myeloid lineage, then the mutations must be serially acquired in clones of HSC. Using primary patient samples and single cell genomic methods, we found evidence of pre-leukemic HSC and mutations, confirming our hypothesis. Furthermore, we showed that these pre-leukemic HSC survive chemotherapy and may give rise to relapsed disease. Thus, these pre-leukemic mutations may be critical targets for curative therapies.

## Teaching

---

### COURSES

#### 2019-20

- Clinical Cancer Research Internship Program: CBIO 246 (Win, Spr)

#### 2018-19

- Clinical Cancer Research Internship Program: CBIO 246 (Win, Spr)

#### 2017-18

- Clinical Cancer Research Internship Program: CBIO 246 (Win, Spr)

### STANFORD ADVISEES

#### Med Scholar Project Advisor

Chris Dove, Ritika Dutta

#### Doctoral Dissertation Reader (AC)

Benson George

#### Orals Chair

Gunsagar Gulati

#### Postdoctoral Faculty Sponsor

Daiki Karigane, Thomas Koehnke, Yusuke Nakauchi, Rajiv Sharma, Jay Spiegel

#### Doctoral Dissertation Advisor (AC)

Brooks Benard, Chris Dove, Asiri Ediriwickrema, Amy Fan, Miles Linde, Kevin Nuno

#### Postdoctoral Research Mentor

Asiri Ediriwickrema, Eric Gars, Thomas Koehnke, Rajiv Sharma

### GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (Phd Program)
- Immunology (Phd Program)
- Stem Cell Biology and Regenerative Medicine (Phd Program)

## Publications

---

### PUBLICATIONS

- **CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.** *The New England journal of medicine*  
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J., Roschewski, M., LaCasce, A., Collins, G. P., Tran, T., Lynn, J., Chen, et al  
2018; 379 (18): 1711–21
- **SY-1425 (tamibarotene), a potent and selective RAR alpha agonist, induces changes in the transcriptional regulatory circuit of AML cells leading to differentiation**  
Fiore, C. M., McKeown, M. R., Lee, E., Eaton, M. L., Smith, D., Austgen, K., Chen, M., Guenther, M., Corces, M., Majeti, R., Olson, E., Fritz, C. C.  
AMER ASSOC CANCER RESEARCH.2017: 29–30
- **Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.** *Cell stem cell*  
Chao, M. P., Gentles, A. J., Chatterjee, S., Lan, F., Reinisch, A., Corces, M. R., Xavy, S., Shen, J., Haag, D., Chanda, S., Sinha, R., Morganti, R. M., Nishimura, et al

2017; 20 (3): 329-344 e7

- **Biology and relevance of human acute myeloid leukemia stem cells.** *Blood*  
Thomas, D., Majeti, R.  
2017
- **Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6.** *eLife*  
Bak, R. O., Dever, D. P., Reinisch, A., Cruz Hernandez, D., Majeti, R., Porteus, M. H.  
2017; 6
- **Super-Enhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML Including an RAR# Dependency Targetable by SY-1425, a Potent and Selective RAR# Agonist.** *Cancer discovery*  
McKeown, M. R., Corces, M. R., Eaton, M. L., Fiore, C., Lee, E., Lopez, J. T., Chen, M. W., Smith, D., Chan, S. M., Koenig, J. L., Austgen, K., Guenther, M. G., Orlando, et al  
2017
- **A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells** *NATURE MEDICINE*  
Reinisch, A., Thomas, D., Corces, M. R., Zhang, X., Gratzinger, D., Hong, W., Schallmoser, K., Strunk, D., Majeti, R.  
2016; 22 (7): 812-821
- **Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation.** *Cell stem cell*  
Mazumdar, C., Shen, Y., Xavy, S., Zhao, F., Reinisch, A., Li, R., Corces, M. R., Flynn, R. A., Buenrostro, J. D., Chan, S. M., Thomas, D., Koenig, J. L., Hong, et al  
2015; 17 (6): 675-688
- **Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
McClellan, J. S., Dove, C., Gentles, A. J., Ryan, C. E., Majeti, R.  
2015; 112 (13): 4074-4079
- **Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.** *Nature medicine*  
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W., Zhao, F., Medeiros, B. C., Tyvoll, D. A., Majeti, R.  
2015; 21 (2): 178-184
- **Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition.** *Blood*  
Sinha, S., Thomas, D., Yu, L., Gentles, A. J., Jung, N., Corces-Zimmerman, M. R., Chan, S. M., Reinisch, A., Feinberg, A. P., Dill, D. L., Majeti, R.  
2015; 125 (2): 316-326
- **Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.** *Proceedings of the National Academy of Sciences of the United States of America*  
Corces-Zimmerman, M. R., Hong, W., Weissman, I. L., Medeiros, B. C., Majeti, R.  
2014; 111 (7): 2548-2553
- **Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia** *SCIENCE TRANSLATIONAL MEDICINE*  
Jan, M., Snyder, T. M., Corces-Zimmerman, M. R., Vyas, P., Weissman, I. L., Quake, S. R., Majeti, R.  
2012; 4 (149)
- **Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*  
Gentles, A. J., Plevritis, S. K., Majeti, R., Alizadeh, A. A.  
2010; 304 (24): 2706-2715
- **Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma** *CELL*  
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., Park, C. Y., Zhao, F., Kohrt, et al  
2010; 142 (5): 699-713
- **CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells** *CELL*  
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., Weissman, I. L.  
2009; 138 (2): 286-299

- **Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood** *CELL STEM CELL*  
Majeti, R., Park, C. Y., Weissman, I. L.  
2007; 1 (6): 635-645
- **Barcoded Clonal Tracking of CRISPR-Cas9 and rAAV6-Mediated Gene Targeting in Human Hematopoietic Stem and Progenitor Cells**  
Dever, D. P., Sharma, R., Lee, C. M., Aziz, A., Koehnke, T., Camarena, J., Pan, Y., Zhao, F., Bao, G., Majeti, R., Porteus, M.  
CELL PRESS.2019: 5
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers** *JOURNAL OF CLINICAL ONCOLOGY*  
Sikic, B., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al  
2019; 37 (12): 946+
- **CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors** *CLINICAL CANCER RESEARCH*  
Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., Rietberg, S. P., Linde, M. H., Xu, P., Rota, C., Sotillo, E., Labanieh, L., Lee, et al  
2019; 25 (8): 2560-74
- **Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA** *ELIFE*  
Xu, J., Nuno, K., Litzenburger, U. M., Qi, Y., Corces, M., Majeti, R., Chang, H. Y.  
2019; 8
- **Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA.** *eLife*  
Xu, J., Nuno, K., Litzenburger, U. M., Qi, Y., Corces, M. R., Majeti, R., Chang, H. Y.  
2019; 8
- **Data mining for mutation-specific targets in acute myeloid leukemia** *LEUKEMIA*  
Benard, B., Gentles, A. J., Kohnke, T., Majeti, R., Thomas, D.  
2019; 33 (4): 826-43
- **No Matter How You Splice It, RBM39 Inhibition Targets Spliceosome Mutant AML.** *Cancer cell*  
Thomas, R., Majeti, R.  
2019; 35 (3): 337-39
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al  
2019: JCO1802018
- **Data mining for mutation-specific targets in acute myeloid leukemia.** *Leukemia*  
Benard, B., Gentles, A. J., Kohnke, T., Majeti, R., Thomas, D.  
2019
- **CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., Rietberg, S. P., Linde, M. H., Xu, P., Rota, C., Sotillo, E., Labanieh, L., Lee, et al  
2019
- **Induced pluripotent stem cell modeling of malignant hematopoiesis.** *Experimental hematology*  
Chao, M. P., Majeti, R.  
2019
- **Targeting Cancer Stemness in the Clinic: From Hype to Hope.** *Cell stem cell*  
Saygin, C., Matei, D., Majeti, R., Reizes, O., Lathia, J. D.  
2018
- **Accumulation of JAK Activation-Loop Phosphorylation Promotes Type I JAK Inhibitor Withdrawal Syndrome in Myelofibrosis**

Tvorogov, D., Thomas, D., Liau, N. D., Dottore, M., Barry, E. F., Lathi, M., Kan, W. L., Hercus, T. R., Stomski, F., Hughes, T. P., Tergaonkar, V., Parker, M. W., Ross, et al  
AMER SOC HEMATOLOGY.2018

- **Macrophage de novo NAD<sup>+</sup> synthesis specifies immune function in aging and inflammation.** *Nature immunology*  
Minhas, P. S., Liu, L., Moon, P. K., Joshi, A. U., Dove, C., Mhatre, S., Contrepois, K., Wang, Q., Lee, B. A., Coronado, M., Bernstein, D., Snyder, M. P., Migaud, et al  
2018
- **Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.** *Science advances*  
Tvorogov, D., Thomas, D., Liau, N. P., Dottore, M., Barry, E. F., Lathi, M., Kan, W. L., Hercus, T. R., Stomski, F., Hughes, T. P., Tergaonkar, V., Parker, M. W., Ross, et al  
2018; 4 (11): eaat3834
- **Identification of the Human Skeletal Stem Cell.** *Cell*  
Chan, C. K., Gulati, G. S., Sinha, R., Tompkins, J. V., Lopez, M., Carter, A. C., Ransom, R. C., Reinisch, A., Wearda, T., Murphy, M., Brewer, R. E., Koepke, L. S., Marecic, et al  
2018; 175 (1): 43
- **Integrated Single-Cell Analysis Maps the Continuous Regulatory Landscape of Human Hematopoietic Differentiation** *CELL*  
Buenrostro, J. D., Corces, M., Lareau, C. A., Wu, B., Schep, A. N., Aryee, M. J., Majeti, R., Chang, H. Y., Greenleaf, W. J.  
2018; 173 (6): 1535-+
- **Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells** *NATURE IMMUNOLOGY*  
Karamitros, D., Stoilova, B., Aboukhalil, Z., Hamey, F., Reinisch, A., Samitsch, M., Quek, L., Otto, G., Repapi, E., Doondeea, J., Usukhbayar, B., Calvo, J., Taylor, et al  
2018; 19 (1): 85-+
- **Engineering complex genotypes in primary haematopoietic cells using Cas9/sgRNA and AAV donor vectors**  
Bak, R. O., Dever, D. P., Reinisch, A., Cruz, D., Majeti, R., Porteus, M. H.  
MARY ANN LIEBERT, INC.2017: A17
- **Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal** *EBIOMEDICINE*  
Valent, P., Akin, C., Arock, M., Bock, C., George, T. I., Galli, S. J., Gotlib, J., Haferlach, T., Hoermann, G., Hermine, O., Jaeger, U., Kenner, L., Kreipe, et al  
2017; 26: 17-24
- **Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia** *FRONTIERS IN ONCOLOGY*  
Corces, M., Chang, H. Y., Majeti, R.  
2017; 7: 263
- **Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.** *Nature communications*  
Sinha, S., Thomas, D., Chan, S., Gao, Y., Brunen, D., Torabi, D., Reinisch, A., Hernandez, D., Chan, A., Rankin, E. B., Bernards, R., Majeti, R., Dill, et al  
2017; 8: 15580-?
- **Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models** *CANCER DISCOVERY*  
Thomas, D., Majeti, R.  
2017; 7 (5): 459-61
- **Disrupting the CD47-SIRP alpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors** *SCIENCE TRANSLATIONAL MEDICINE*  
Gholamin, S., Mitra, S. S., Feroze, A. H., Liu, J., Kahn, S. A., Zhang, M., Esparza, R., Richard, C., Ramaswamy, V., Remke, M., Volkmer, A. K., Willingham, S., Ponnuswami, et al  
2017; 9 (381)
- **The role of mutations in the cohesin complex in acute myeloid leukemia** *INTERNATIONAL JOURNAL OF HEMATOLOGY*  
Mazumdar, C., Majeti, R.  
2017; 105 (1): 31-36
- **Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.** *EBioMedicine*  
Valent, P., Akin, C., Arock, M., Bock, C., George, T. I., Galli, S. J., Gotlib, J., Haferlach, T., Hoermann, G., Hermine, O., Jäger, U., Kenner, L., Kreipe, et al  
2017; 26: 17-24

- **Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models.** *Cancer discovery*  
Thomas, D., Majeti, R.  
2017; 7 (5): 459–61
- **Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice.** *Nature protocols*  
Reinisch, A., Hernandez, D. C., Schallmoser, K., Majeti, R.  
2017; 12 (10): 2169–88
- **The CD47 Macrophage Checkpoint as a New Immunotherapy Target**  
Sikic, B. I., Padda, S. K., Shah, S. A., Colevas, D., Narayanan, S., Fisher, G. A., Supan, D., Wakelee, H. A., Aoki, R., Pegram, M. D., Villalobos, V. M., Liu, J., Takimoto, et al  
ELSEVIER SCIENCE INC.2017: S108–S109
- **Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes** *ONCOTARGET*  
Matre, P., Velez, J., Jacamo, R., Qi, Y., Su, X., Cai, T., Chan, S. M., Lodi, A., Sweeney, S. R., Ma, H., Davis, R. E., Baran, N., Haferlach, et al  
2016; 7 (48): 79708-79721
- **Sticking It to the Niche: CD98 Mediates Critical Adhesive Signals in AML** *CANCER CELL*  
Reinisch, A., Majeti, R.  
2016; 30 (5): 662–64
- **CRISPR/Cas9  $\beta$ -globin gene targeting in human haematopoietic stem cells.** *Nature*  
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., Uchida, N., Hendel, A., Narla, et al  
2016
- **The role of mutations in the cohesin complex in acute myeloid leukemia.** *International journal of hematology*  
Mazumdar, C., Majeti, R.  
2016: -?
- **SIRP alpha-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells** *CLINICAL CANCER RESEARCH*  
Piccione, E. C., Juarez, S., Tseng, S., Liu, J., Stafford, M., Narayanan, C., Wang, L., Weiskopf, K., Majeti, R.  
2016; 22 (20): 5109-5119
- **Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells.** *Oncotarget*  
Huang, M., Garcia, J. S., Thomas, D., Zhu, L., Nguyen, L. X., Chan, S. M., Majeti, R., Medeiros, B. C., Mitchell, B. S.  
2016
- **Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution.** *Nature genetics*  
Corces, M. R., Buenrostro, J. D., Wu, B., Greenside, P. G., Chan, S. M., Koenig, J. L., Snyder, M. P., Pritchard, J. K., Kundaje, A., Greenleaf, W. J., Majeti, R., Chang, H. Y.  
2016; 48 (10): 1193-1203
- **Burning Fat Fuels Leukemic Stem Cell Heterogeneity.** *Cell stem cell*  
Thomas, D., Majeti, R.  
2016; 19 (1): 1-2
- **ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.** *Cancer discovery*  
Zhu, L., Li, Q., Wong, S. H., Huang, M., Klein, B. J., Shen, J., Ikenouye, L., Onishi, M., Schneidawind, D., Buechele, C., Hansen, L., Duque-Afonso, J., Zhu, et al  
2016; 6 (7): 770-783
- **CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer** *JOURNAL OF CLINICAL INVESTIGATION*  
Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J., Liu, J., Lim, J. S., Yang, D., Seitz, G., Thuyen Nguyen, et al  
2016; 126 (7): 2610-2620
- **SUPER-ENHANCER ANALYSIS DEFINES NOVEL AML AND MDS SUB-TYPES SENSITIVE TO SY-1425, A POTENT AND SELECTIVE RARA AGONIST**  
Mckeown, M., Lee, E., Fiore, C., Eaton, M., Lopez, J., Corces-Zimmerman, R., Majeti, R., Stephens, K., Fritz, C., Olson, E.  
FERRATA STORTI FOUNDATION.2016: 325

- **FACS-Based Enrichment of a Highly Purified HBB-Targeted Hematopoietic Stem and Progenitor Cell Population Using rAAV6 and CRISPR/Cas9**  
Dever, D. P., Bak, R. O., Camarena, J., Saxena, N., Reinisch, A., Nicolas, C. E., Wilkens, A. B., Hendel, A., Uchida, N., Majeti, R., Weinberg, K. I., Porteus, M. H.  
NATURE PUBLISHING GROUP.2016: S17
- **CRISPR/Cas9 and rAAV6-Mediated Targeted Integration at the CCR5 Locus in Hematopoietic Stem and Progenitor Cells**  
Bak, R. O., Dever, D. P., Saxena, N., Camarena, J., Reinisch, A., Wilkens, A. B., Nicolas, C. E., Hendel, A., Majeti, R., Weinberg, K. I., Porteus, M. H.  
NATURE PUBLISHING GROUP.2016: S19
- **Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo** *PLOS ONE*  
Zhang, M., Hutter, G., Kahn, S. A., Azad, T. D., Gholamin, S., Xu, C. Y., Liu, J., Achrol, A. S., Richard, C., Sommerkamp, P., Schoen, M. K., McCracken, M. N., Majeti, et al  
2016; 11 (4)
- **Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity.** *PLoS one*  
Jonas, B. A., Johnson, C., Gratzinger, D., Majeti, R.  
2016; 11 (7)
- **Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia** *EXPERIMENTAL HEMATOLOGY*  
Sykes, S. M., Kokkalis, K. D., Milsom, M. D., Levine, R. L., Majeti, R.  
2015; 43 (12): 989–92
- **Deciphering the cancer methylome with Boolean implications to find novel drivers of aberrant DNA methylation and actionable drug targets**  
Sinha, S., Thomas, D., Majeti, R., Dill, D. L.  
AMER ASSOC CANCER RESEARCH.2015
- **An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis** *NATURE COMMUNICATIONS*  
Jung, N., Dai, B., Gentles, A. J., Majeti, R., Feinberg, A. P.  
2015; 6
- **A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells** *MABS*  
Piccione, E. C., Juarez, S., Liu, J., Tseng, S., Ryan, C. E., Narayanan, C., Wang, L., Weiskopf, K., Majeti, R.  
2015; 7 (5): 946-956
- **Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells** *SEMINARS IN HEMATOLOGY*  
Reinisch, A., Chan, S. M., Thomas, D., Majeti, R.  
2015; 52 (3): 150-164
- **Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands** *CELL*  
Moraga, I., Wernig, G., Wilmes, S., Gryshkova, V., Richter, C. P., Hong, W., Sinha, R., Guo, F., Fabionar, H., Wehrman, T. S., Krutzik, P., Demharter, S., Plo, et al  
2015; 160 (6): 1196-1208
- **Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation.** *Blood*  
Reinisch, A., Etchart, N., Thomas, D., Hofmann, N. A., Fruehwirth, M., Sinha, S., Chan, C. K., Senarath-Yapa, K., Seo, E., Wearda, T., Hartwig, U. F., Beham-Schmid, C., Trajanoski, et al  
2015; 125 (2): 249-260
- **Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab** *AMERICAN JOURNAL OF HEMATOLOGY*  
Chao, M. P., Hong, J., Kunder, C., Lester, L., Schrier, S. L., Majeti, R.  
2015; 90 (1): 78-81
- **A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.** *mAbs*  
Piccione, E. C., Juarez, S., Liu, J., Tseng, S., Ryan, C. E., Narayanan, C., Wang, L., Weiskopf, K., Majeti, R.  
2015; 7 (5): 946-956
- **Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.** *PLoS one*  
Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., Willingham, S., Howard, M., Prohaska, S., Volkmer, J., Chao, M., Weissman, I. L., Majeti, et al  
2015; 10 (9)



- **Mutation in Wilms' Tumor 1 Induces DNA Hypermethylation of PRC2 Targets, Blocks Myelomonocytic Differentiation, and Defines a Novel Subtype of AML Responsive to EZH2 Inhibition**  
Thomas, D., Sinha, S., Yu, L., Jung, N., Dai, B., Gentles, A. J., Feinberg, A. P., Dill, D., Majeti, R.  
AMER SOC HEMATOLOGY.2014
- **Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis** *LEUKEMIA*  
Corces-Zimmerman, M. R., Majeti, R.  
2014; 28 (12): 2276-2282
- **Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia** *BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY*  
Majeti, R.  
2014; 27 (3-4): 229-234
- **WILMS' TUMOR 1 MUTATION DRIVES DNA HYPERMETHYLATION IN AML AND RESPONDS TO EZH2-INHIBITOR**  
Thomas, D., Sinha, S., Gentles, A., Jung, N., Feinberg, A., Dill, D., Majeti, R.  
ELSEVIER SCIENCE INC.2014: S62
- **Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells.** *Blood*  
Nguyen, L. X., Chan, S. M., Ngo, T. D., Raval, A., Kim, K. K., Majeti, R., Mitchell, B. S.  
2014; 124 (4): 579-589
- **Proffered Paper: Overcoming immune evasion in ovarian and breast cancer with anti-CD47 antibody blockade: A novel class of immune therapy**  
Volkmer, A. K., Willingham, S. B., Tseng, S. R., Ho, P. Y., Volkmer, J. P., Sikic, B. I., Majeti, R., Weissman, I. L.  
ELSEVIER SCI LTD.2014: S13
- **Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma** *NATURE COMMUNICATIONS*  
Green, M. R., Vicente-Duenas, C., Romero-Camarero, I., Liu, C. L., Dai, B., Gonzalez-Herrero, I., Garcia-Ramirez, I., Alonso-Escudero, E., Iqbal, J., Chan, W. C., Campos-Sanchez, E., Orfao, A., Pintado, et al  
2014; 5
- **OVERCOMING IMMUNE EVASION IN PEDIATRIC BRAIN TUMORS: A PRE-CLINICAL DEVELOPMENT STUDY USING A HUMANIZED ANTI-CD47 ANTIBODY**  
Gholamin, S., Mitra, S., Feroze, A., Zhang, M., Esparza, R., Kahn, S., Richard, C., Achrol, A., Volkmer, A., Liu, J., Volkmer, J., Majeti, R., Weissman, et al  
OXFORD UNIV PRESS INC.2014: 138
- **Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.** *PloS one*  
Lee, J. Y., Hong, W., Majeti, R., Stearns, T.  
2014; 9 (3)
- **Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.** *Best practice & research. Clinical haematology*  
Majeti, R.  
2014; 27 (3-4): 229-34
- **Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.** *PloS one*  
Lee, J. Y., Hong, W., Majeti, R., Stearns, T.  
2014; 9 (3)
- **Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.** *Nature communications*  
Green, M. R., Vicente-Dueñas, C., Romero-Camarero, I., Long Liu, C., Dai, B., González-Herrero, I., García-Ramírez, I., Alonso-Escudero, E., Iqbal, J., Chan, W. C., Campos-Sanchez, E., Orfao, A., Pintado, et al  
2014; 5: 3904-?
- **Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia** *INTERNATIONAL JOURNAL OF HEMATOLOGY*  
Chan, S. M., Majeti, R.  
2013; 98 (6): 648-657
- **Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib** *LEUKEMIA*  
Huang, M., Thomas, D., Li, M. X., Feng, W., Chan, S. M., Majeti, R., Mitchell, B. S.  
2013; 27 (10): 1970-1980

- **CD99 IDENTIFIES DISEASE STEM CELLS IN ACUTE MYELOID LEUKEMIA (AML) AND THE MYELODYSPLASTIC SYNDROMES (MDS)**  
Chung, S., Pang, W., Jan, M., Klimek, V., Weissman, I., Majeti, R., Park, C.  
ELSEVIER SCIENCE INC.2013: S16
- **Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia** *LEUKEMIA*  
Craddock, C., Quek, L., Goardon, N., Freeman, S., Siddique, S., Raghavan, M., Aztberger, A., Schuh, A., Grimwade, D., IVEY, A., Virgo, P., Hills, R., McSkeane, et al  
2013; 27 (5): 1028-1036
- **Clonal evolution of acute leukemia genomes** *ONCOGENE*  
Jan, M., Majeti, R.  
2013; 32 (2): 135-140
- **The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould.** *EMBO molecular medicine*  
McClellan, J. S., Majeti, R.  
2013; 5 (1): 7-9
- **Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen** *BLOOD*  
Ochsenreither, S., Majeti, R., Schmitt, T., Stirewalt, D., Keilholz, U., Loeb, K. R., Wood, B., Choi, Y. E., Bleakley, M., Warren, E. H., Hudecek, M., Akatsuka, Y., Weissman, et al  
2012; 119 (23): 5492-5501
- **The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Willingham, S. B., Volkmer, J., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., Lovelace, P., Scheeren, F. A., Chao, et al  
2012; 109 (17): 6662-6667
- **Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Edris, B., Weiskopf, K., Volkmer, A. K., Volkmer, J., Willingham, S. B., Contreras-Trujillo, H., Liu, J., Majeti, R., West, R. B., Fletcher, J. A., Beck, A. H., Weissman, I. L., van de Rijn, et al  
2012; 109 (17): 6656-6661
- **Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia**  
Jan, M., Snyder, T. M., Corces-Zimmerman, M., Weissman, I. L., Quake, S. R., Majeti, R.  
AMER ASSOC CANCER RESEARCH.2012
- **The CD47-SIRP alpha pathway in cancer immune evasion and potential therapeutic implications** *CURRENT OPINION IN IMMUNOLOGY*  
Chao, M. P., Weissman, I. L., Majeti, R.  
2012; 24 (2): 225-232
- **Programmed cell removal: a new obstacle in the road to developing cancer.** *Nature reviews. Cancer*  
Chao, M. P., Majeti, R., Weissman, I. L.  
2012; 12 (1): 58-67
- **Programmed cell removal: a new obstacle in the road to developing cancer** *NATURE REVIEWS CANCER*  
Chao, M. P., Majeti, R., Weissman, I. L.  
2012; 12 (1): 58-67
- **Treatment advances have not improved the early death rate in acute promyelocytic leukemia** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*  
McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., Alizadeh, A. A., Medeiros, B. C.  
2012; 97 (1): 133-136
- **Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy** *BLOOD*  
Chao, M. P., Tang, C., Pachynski, R. K., Chin, R., Majeti, R., Weissman, I. L.  
2011; 118 (18): 4890-4901
- **Surprise! HSC Are Aberrant in Chronic Lymphocytic Leukemia** *CANCER CELL*  
Alizadeh, A. A., Majeti, R.

2011; 20 (2): 135-136

- **Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments** *BLOOD*  
Gibbs, K. D., Gilbert, P. M., Sachs, K., Zhao, F., Blau, H. M., Weissman, I. L., Nolan, G. P., Majeti, R.  
2011; 117 (16): 4226-4233
- **Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Jan, M., Chao, M. P., Cha, A. C., Alizadeh, A. A., Gentes, A. J., Weissman, I. L., Majeti, R.  
2011; 108 (12): 5009-5014
- **Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells** *ONCOGENE*  
Majeti, R.  
2011; 30 (9): 1009-1019
- **Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia** *CANCER RESEARCH*  
Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., Park, C. Y., Weissman, I. L., Majeti, R.  
2011; 71 (4): 1374-1384
- **Human Acute Myelogenous Leukemia Stem Cells Revisited: There's More Than Meets the Eye** *CANCER CELL*  
Majeti, R., Weissman, I. L.  
2011; 19 (1): 9-10
- **Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47** *SCIENCE TRANSLATIONAL MEDICINE*  
Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentes, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., Majeti, R., Weissman, I. L.  
2010; 2 (63)
- **Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience** *AMERICAN JOURNAL OF HEMATOLOGY*  
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., Gotlib, J., Coutre, S., Liedtke, M., Berube, C., Alizadeh, A. A., Medeiros, B. C.  
2010; 85 (11): 877-881
- **Metastatic Cancer Stem Cells: An Opportunity for Improving Cancer Treatment?** *CELL STEM CELL*  
Diehn, M., Majeti, R.  
2010; 6 (6): 502-503
- **Macrophages as mediators of tumor immunosurveillance** *TRENDS IN IMMUNOLOGY*  
Jaiswal, S., Chao, M. P., Majeti, R., Weissman, I. L.  
2010; 31 (6): 212-219
- **Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)** *LEUKEMIA RESEARCH*  
Medeiros, B. C., Kohrt, H. E., Arber, D. A., Bangs, C. D., Cherry, A. M., Majeti, R., Kogel, K. E., Azar, C. A., Patel, S., Alizadeh, A. A.  
2010; 34 (5): 594-597
- **Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*  
Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., Kohrt, H. E., Medeiros, B. C.  
AMER SOC HEMATOLOGY.2009: 420-21
- **Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*  
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., Coutre, S., Medeiros, B. C., Alizadeh, A. A.  
AMER SOC HEMATOLOGY.2009: 646-47
- **CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis** *CELL*  
Jaiswal, S., Jamieson, C. H., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D., van Rooijen, N., Weissman, I. L.  
2009; 138 (2): 271-285
- **Dysregulated gene expression networks in human acute myelogenous leukemia stem cells** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*

Majeti, R., Becker, M. W., Tian, Q., Lee, T. M., Yan, X., Liu, R., Chiang, J., Hood, L., Clarke, M. F., Weissman, I. L.  
2009; 106 (9): 3396-3401

● **The Adhesion Molecule Esam1 Is a Novel Hematopoietic Stem Cell Marker** *STEM CELLS*

Ooi, A. G., Karsunky, H., Majeti, R., Butz, S., Vestweber, D., Ishida, T., Quertermous, T., Weissman, I. L., Forsberg, E. C.  
2009; 27 (3): 653-661

● **In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood** *NATURE PROTOCOLS*

Park, C. Y., Majeti, R., Weissman, I. L.  
2008; 3 (12): 1932-1940